News | June 23, 2008

FDA Grants CLIA Waiver to HemoCue for CAD Diagnosis

June 20, 2008 - HemoCue AB reported that the FDA granted the HemoCue Albumin 201 System, a quantitative point-of-care test for screening, diagnosing and monitoring microalbuminuria, a CLIA waiver, enabling the use of the test kit in any healthcare facility with a CLIA Certificate of Waiver in the U.S.
Microalbuminuria may indicate the presence of chronic kidney disease (CKD), and the risk of developing cardiovascular disease in patients with or without diabetes or hypertension.
“Given that microalbuminuria is a risk marker for cardiovascular disease, and its increase over time can indicate kidney disease, it is important that physicians have a fast, easy, reliable test to assess changes in their patients,” said professor George L. Bakris, M.D., Director of the Hypertensive Diseases Unit at the University of Chicago-Pritzker School of Medicine. “The availability of a point-of-care test that accurately measures albumin in urine is expected to have a positive impact on physicians' ability to screen in-office and then begin treatment for patients at risk for microalbuminuria, such as those with diabetes or hypertension.”
Microalbuminuria is a condition characterized by the presence of albumin, a protein, excreted in urine. As the albumin excretion increases, so does the risk of CKD or cardiovascular disease onset and progression. The HemoCue Albumin 201 System, which produces results within 90 seconds, enables physicians to identify and quantify low levels of albumin at the point of care for the purpose of screening for, diagnosing, monitoring and to supplement clinical evidence in the treatment of microalbuminuria. Unlike semiquantitative urine "dipstick" methods, which indicate if a patient's microalbumin levels fall within pre-defined ranges, the HemoCue Albumin 201 System provides the actual concentration present in the sample. Using the HemoCue Albumin 201 System, physicians may monitor changes in microalbumin excretion in a patient over time.
A study in the American Journal of Nephrology (2008;28:324-329) published online in November 2007 concluded that the "HemoCue Albumin 201 System is a valid and precise method for UAE (urinary albumin excretion) determination, exhibiting a performance similar to laboratory ACR (albumin-to-creatinine) estimations and far better than the widely used dipsticks ... the HemoCue Albumin 201 System appears to be a convenient solution for detection of abnormal UAE levels." The study involved 165 adult subjects under treatment for hypertension at the Rush University Medical Center in Chicago. Dr. Bakris was the study’s lead investigator. HemoCue AB financially supported the study.

For more information: www.hemocue.com

Related Content

Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing | July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing | July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
HyperMed Imaging, HyperView portable tissue oxygenation measurement system, FDA clearance
Technology | Point of Care Testing | January 27, 2017
HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat
Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology
INRatio, Alere, Abbott, I and R testing, INR testing
Feature | Point of Care Testing | December 07, 2016
December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substanti
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing | November 10, 2016
Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-held portable...
Abbott, Alere, acquisition, point of care diagnostics
News | Point of Care Testing | February 03, 2016
Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms of the agreement,...
News | Point of Care Testing | December 22, 2015
Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI)...
The Lancet results, Abbott ARCHITECT STAT High Sensitive Troponin-I test, rule out myocardial infarction, Accident and Emergency, A&E
News | Point of Care Testing | October 13, 2015
The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may rule...
Overlay Init